Analyzing Insulet (NASDAQ:PODD) & Demant A/S (OTCMKTS:WILYY)

Demant A/S (OTCMKTS:WILYY) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.

Valuation & Earnings

This table compares Demant A/S and Insulet”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Demant A/S	$3.48 billion	2.52	$233.91 million	N/A	N/A
Insulet	$2.71 billion	4.20	$247.10 million	$4.30	38.15

Insulet has lower revenue, but higher earnings than Demant A/S.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Demant A/S and Insulet, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Demant A/S	0	1	1	1	3.00
Insulet	2	4	22	0	2.71

Insulet has a consensus target price of $235.25, suggesting a potential upside of 43.39%. Given Insulet’s higher probable upside, analysts clearly believe Insulet is more favorable than Demant A/S.

Volatility and Risk

Demant A/S has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Insulet has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.

Profitability

This table compares Demant A/S and Insulet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Demant A/S	N/A	N/A	N/A
Insulet	10.44%	26.87%	12.01%

Summary

Insulet beats Demant A/S on 7 of the 11 factors compared between the two stocks.

About Demant A/S

Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment is involved in the manufacturing, servicing, and sale of hearing aids, and diagnostic products and services. The Communications segment provides headsets and solutions for the professional call centers, office markets, and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.